Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Joel Chuku, Olajide Ojo, Petra Mariaria, Uthman Alao, Raolat Adenike Salami, Michael Oladunjoye
{"title":"chandpura病毒在印度卷土重来:对诊断工具、抗病毒药物开发和公共卫生影响的见解。","authors":"Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Joel Chuku, Olajide Ojo, Petra Mariaria, Uthman Alao, Raolat Adenike Salami, Michael Oladunjoye","doi":"10.1155/ghe3/1015031","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly <i>Phlebotomus</i> spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. <b>Main Body of Abstract:</b> This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. <b>Conclusion:</b> Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.</p>","PeriodicalId":44052,"journal":{"name":"Global Health Epidemiology and Genomics","volume":"2025 ","pages":"1015031"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037235/pdf/","citationCount":"0","resultStr":"{\"title\":\"Chandipura Virus Resurgence in India: Insights Into Diagnostic Tools, Antiviral Development, and Public Health Implications.\",\"authors\":\"Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Joel Chuku, Olajide Ojo, Petra Mariaria, Uthman Alao, Raolat Adenike Salami, Michael Oladunjoye\",\"doi\":\"10.1155/ghe3/1015031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly <i>Phlebotomus</i> spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. <b>Main Body of Abstract:</b> This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. <b>Conclusion:</b> Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.</p>\",\"PeriodicalId\":44052,\"journal\":{\"name\":\"Global Health Epidemiology and Genomics\",\"volume\":\"2025 \",\"pages\":\"1015031\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037235/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Health Epidemiology and Genomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/ghe3/1015031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Health Epidemiology and Genomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ghe3/1015031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Chandipura Virus Resurgence in India: Insights Into Diagnostic Tools, Antiviral Development, and Public Health Implications.
Background: Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly Phlebotomus spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. Main Body of Abstract: This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. Conclusion: Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.